Stem Cell Clinic

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market overview with detailed analysis, competitive landscape, forecast to 2026 – WhaTech…

By Stell Cell Research

Complete study of the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape.

This report offers a clear understanding of the present as well as future scenario of the global Platelet Rich Plasma and Stem Cell Alopecia Treatment industry. Research techniques like PESTLE and Porters Five Forces analysis have been deployed by the researchers. They have also provided accurate data on Platelet Rich Plasma and Stem Cell Alopecia Treatment production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.

Key companies operating in the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market include _Kerastem, Eclipse, Regen Lab SA, Stemcell Technologies, RepliCel Life Sciences, Histogen, Glofinn Oy., ... Platelet Rich Plasma and Stem Cell Alopecia Treatment

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

http://www.qyresearch.com/index/dent-market

Segmental Analysis

The report has classified the global Platelet Rich Plasma and Stem Cell Alopecia Treatment industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Platelet Rich Plasma and Stem Cell Alopecia Treatment manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Platelet Rich Plasma and Stem Cell Alopecia Treatment industry.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Segment By Type:

, Androgenic Alopecia, Congenital Alopecia, Cicatricial Or Scarring Alopecia

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Segment By Application:

, Hospital, Dermatology Clinic, Other

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Platelet Rich Plasma and Stem Cell Alopecia Treatment industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market include _Kerastem, Eclipse, Regen Lab SA, Stemcell Technologies, RepliCel Life Sciences, Histogen, Glofinn Oy., ...

Platelet Rich Plasma and Stem Cell Alopecia Treatment

Key questions answered in the report:

Enquire Customization in The Report: http://www.qyresearch.com/customient-market

TOC

1 Study Coverage1.1 Platelet Rich Plasma and Stem Cell Alopecia Treatment Product Introduction1.2 Market Segments1.3 Key Platelet Rich Plasma and Stem Cell Alopecia Treatment Manufacturers Covered: Ranking by Revenue1.4 Market by Type1.4.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Growth Rate by Type1.4.2 Androgenic Alopecia1.4.3 Congenital Alopecia1.4.4 Cicatricial Or Scarring Alopecia1.5 Market by Application1.5.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Growth Rate by Application1.5.2 Hospital1.5.3 Dermatology Clinic1.5.4 Other1.6 Coronavirus Disease 2019 (Covid-19): Platelet Rich Plasma and Stem Cell Alopecia Treatment Industry Impact1.6.1 How the Covid-19 is Affecting the Platelet Rich Plasma and Stem Cell Alopecia Treatment Industry1.6.1.1 Platelet Rich Plasma and Stem Cell Alopecia Treatment Business Impact Assessment - Covid-191.6.1.2 Supply Chain Challenges1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and Platelet Rich Plasma and Stem Cell Alopecia Treatment Potential Opportunities in the COVID-19 Landscape1.6.3 Measures / Proposal against Covid-191.6.3.1 Government Measures to Combat Covid-19 Impact1.6.3.2 Proposal for Platelet Rich Plasma and Stem Cell Alopecia Treatment Players to Combat Covid-19 Impact 1.7 Study Objectives 1.8 Years Considered 2 Executive Summary2.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Estimates and Forecasts2.1.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue 2015-20262.1.2 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales 2015-20262.2 Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size by Region: 2020 Versus 20262.2.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Retrospective Market Scenario in Sales by Region: 2015-20203.1 Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Manufacturers3.1.1 Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Manufacturers (2015-2020)3.1.2 Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Market Share by Manufacturers (2015-2020)3.2 Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Manufacturers3.2.1 Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Manufacturers (2015-2020)3.2.2 Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Share by Manufacturers (2015-2020)3.2.3 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Concentration Ratio (CR5 and HHI) (2015-2020)3.2.4 Global Top 10 and Top 5 Companies by Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue in 20193.2.5 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Platelet Rich Plasma and Stem Cell Alopecia Treatment Price by Manufacturers3.4 Platelet Rich Plasma and Stem Cell Alopecia Treatment Manufacturing Base Distribution, Product Types3.4.1 Platelet Rich Plasma and Stem Cell Alopecia Treatment Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers Platelet Rich Plasma and Stem Cell Alopecia Treatment Product Type3.4.3 Date of International Manufacturers Enter into Platelet Rich Plasma and Stem Cell Alopecia Treatment Market 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size by Type (2015-2020)4.1.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Type (2015-2020)4.1.2 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Type (2015-2020)4.1.3 Platelet Rich Plasma and Stem Cell Alopecia Treatment Average Selling Price (ASP) by Type (2015-2026)4.2 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast by Type (2021-2026)4.2.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Forecast by Type (2021-2026)4.2.2 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Forecast by Type (2021-2026)4.2.3 Platelet Rich Plasma and Stem Cell Alopecia Treatment Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Breakdown Data by Application (2015-2026)5.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size by Application (2015-2020)5.1.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Application (2015-2020)5.1.2 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Application (2015-2020)5.1.3 Platelet Rich Plasma and Stem Cell Alopecia Treatment Price by Application (2015-2020)5.2 Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast by Application (2021-2026)5.2.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Forecast by Application (2021-2026)5.2.2 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Forecast by Application (2021-2026)5.2.3 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Price Forecast by Application (2021-2026) 6 North America6.1 North America Platelet Rich Plasma and Stem Cell Alopecia Treatment by Country6.1.1 North America Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Country6.1.2 North America Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Country6.1.3 U.S.6.1.4 Canada6.2 North America Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Type6.3 North America Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Application 7 Europe7.1 Europe Platelet Rich Plasma and Stem Cell Alopecia Treatment by Country7.1.1 Europe Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Country7.1.2 Europe Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Country7.1.3 Germany7.1.4 France7.1.5 U.K.7.1.6 Italy7.1.7 Russia7.2 Europe Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Type7.3 Europe Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Application 8 Asia Pacific8.1 Asia Pacific Platelet Rich Plasma and Stem Cell Alopecia Treatment by Region8.1.1 Asia Pacific Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Region8.1.2 Asia Pacific Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Region8.1.3 China8.1.4 Japan8.1.5 South Korea8.1.6 India8.1.7 Australia8.1.8 Taiwan8.1.9 Indonesia8.1.10 Thailand8.1.11 Malaysia8.1.12 Philippines8.1.13 Vietnam8.2 Asia Pacific Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Type8.3 Asia Pacific Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Application 9 Latin America9.1 Latin America Platelet Rich Plasma and Stem Cell Alopecia Treatment by Country9.1.1 Latin America Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Country9.1.2 Latin America Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Country9.1.3 Mexico9.1.4 Brazil9.1.5 Argentina9.2 Central & South America Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Type9.3 Central & South America Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Application 10 Middle East and Africa10.1 Middle East and Africa Platelet Rich Plasma and Stem Cell Alopecia Treatment by Country10.1.1 Middle East and Africa Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Country10.1.2 Middle East and Africa Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Country10.1.3 Turkey10.1.4 Saudi Arabia10.1.5 U.A.E10.2 Middle East and Africa Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Type10.3 Middle East and Africa Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Application 11 Company Profiles11.1 Kerastem11.1.1 Kerastem Corporation Information11.1.2 Kerastem Description, Business Overview and Total Revenue11.1.3 Kerastem Sales, Revenue and Gross Margin (2015-2020)11.1.4 Kerastem Platelet Rich Plasma and Stem Cell Alopecia Treatment Products Offered11.1.5 Kerastem Recent Development11.2 Eclipse11.2.1 Eclipse Corporation Information11.2.2 Eclipse Description, Business Overview and Total Revenue11.2.3 Eclipse Sales, Revenue and Gross Margin (2015-2020)11.2.4 Eclipse Platelet Rich Plasma and Stem Cell Alopecia Treatment Products Offered11.2.5 Eclipse Recent Development11.3 Regen Lab SA11.3.1 Regen Lab SA Corporation Information11.3.2 Regen Lab SA Description, Business Overview and Total Revenue11.3.3 Regen Lab SA Sales, Revenue and Gross Margin (2015-2020)11.3.4 Regen Lab SA Platelet Rich Plasma and Stem Cell Alopecia Treatment Products Offered11.3.5 Regen Lab SA Recent Development11.4 Stemcell Technologies11.4.1 Stemcell Technologies Corporation Information11.4.2 Stemcell Technologies Description, Business Overview and Total Revenue11.4.3 Stemcell Technologies Sales, Revenue and Gross Margin (2015-2020)11.4.4 Stemcell Technologies Platelet Rich Plasma and Stem Cell Alopecia Treatment Products Offered11.4.5 Stemcell Technologies Recent Development11.5 RepliCel Life Sciences11.5.1 RepliCel Life Sciences Corporation Information11.5.2 RepliCel Life Sciences Description, Business Overview and Total Revenue11.5.3 RepliCel Life Sciences Sales, Revenue and Gross Margin (2015-2020)11.5.4 RepliCel Life Sciences Platelet Rich Plasma and Stem Cell Alopecia Treatment Products Offered11.5.5 RepliCel Life Sciences Recent Development11.6 Histogen11.6.1 Histogen Corporation Information11.6.2 Histogen Description, Business Overview and Total Revenue11.6.3 Histogen Sales, Revenue and Gross Margin (2015-2020)11.6.4 Histogen Platelet Rich Plasma and Stem Cell Alopecia Treatment Products Offered11.6.5 Histogen Recent Development11.7 Glofinn Oy.11.7.1 Glofinn Oy. Corporation Information11.7.2 Glofinn Oy. Description, Business Overview and Total Revenue11.7.3 Glofinn Oy. Sales, Revenue and Gross Margin (2015-2020)11.7.4 Glofinn Oy. Platelet Rich Plasma and Stem Cell Alopecia Treatment Products Offered11.7.5 Glofinn Oy. Recent Development11.1 Kerastem11.1.1 Kerastem Corporation Information11.1.2 Kerastem Description, Business Overview and Total Revenue11.1.3 Kerastem Sales, Revenue and Gross Margin (2015-2020)11.1.4 Kerastem Platelet Rich Plasma and Stem Cell Alopecia Treatment Products Offered11.1.5 Kerastem Recent Development 12 Future Forecast by Regions (Countries) (2021-2026)12.1 Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Estimates and Projections by Region12.1.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Forecast by Regions 2021-202612.1.2 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Forecast by Regions 2021-202612.2 North America Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast (2021-2026)12.2.1 North America: Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Forecast (2021-2026)12.2.2 North America: Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Forecast (2021-2026)12.2.3 North America: Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast by Country (2021-2026)12.3 Europe Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast (2021-2026)12.3.1 Europe: Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Forecast (2021-2026)12.3.2 Europe: Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Forecast (2021-2026)12.3.3 Europe: Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast by Country (2021-2026)12.4 Asia Pacific Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast (2021-2026)12.4.1 Asia Pacific: Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Forecast (2021-2026)12.4.2 Asia Pacific: Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Forecast (2021-2026)12.4.3 Asia Pacific: Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast by Region (2021-2026)12.5 Latin America Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast (2021-2026)12.5.1 Latin America: Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Forecast (2021-2026)12.5.2 Latin America: Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Forecast (2021-2026)12.5.3 Latin America: Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast by Country (2021-2026)12.6 Middle East and Africa Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast (2021-2026)12.6.1 Middle East and Africa: Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Forecast (2021-2026)12.6.2 Middle East and Africa: Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Forecast (2021-2026)12.6.3 Middle East and Africa: Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast by Country (2021-2026) 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key Platelet Rich Plasma and Stem Cell Alopecia Treatment Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis 14.1 Value Chain Analysis14.2 Platelet Rich Plasma and Stem Cell Alopecia Treatment Customers 14.3 Sales Channels Analysis 14.3.1 Sales Channels 14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix 16.1 Research Methodology 16.1.1 Methodology/Research Approach 16.1.2 Data Source 16.2 Author Details

This email address is being protected from spambots. You need JavaScript enabled to view it.

Visit link:
Platelet Rich Plasma and Stem Cell Alopecia Treatment Market overview with detailed analysis, competitive landscape, forecast to 2026 - WhaTech...

Update: Pacific Beach Elementary student’s ongoing battle with leukemia – A few months ago we introduced you to Ace Pringle the first-grader from…

By Stell Cell Research

Ace, first-grader at Pacific Beach Elementary, and his 3-year-old younger brother, Crue.

A few months ago, we introduced you to Ace Pringle, the first-grader from Pacific Beach Elementary who is battling Multiple Phenotype Acute Leukemia. Since then, Ace has been going through chemotherapy treatments and hoping for remission.

Recently, Aces doctors recommended that he get a bone marrow transplant.

With a bone marrow transplant, the Pringle family has a few different options to get a donation. They could sign up for the national registry, look into stem cell research, or find a donor. Just this Tuesday, the Pringle family found out that Aces 3-year-old brother, Crue, is a perfect match.

These next steps are going to be difficult, but the fact that Crues a match is huge, says Ace and Crues mother, Amber Pringle. As I look at this rambunctious 3-year-old, he has no idea whats to come for him.

While Ace has been going through chemotherapy, COVID-19 has swept across the world; but the Pringle family did not need to change their lifestyle as the city shut down. When COVID-19 came, we were already living on lockdown. We were already wearing masks to the store, says Amber. Its interesting that everything has caught up with us. Its so surreal.

Additionally, the virus has brought a silver lining to Aces battle with leukemia. Ace has been able to join his first-grade class at PB Elementary with distance learning, says Aces father, John Pringle.

Ace was homeschooled before the San Diego Unified School District stopped in-person classes due to COVID-19. Now, because of the shift to online learning, Ace has been able to rejoin his first-grade class on Zoom.

Its been nice for Ace to join his classmates, says John Pringle. He enjoys connecting with all his classmates all on one screen.

Never would I have imagined that all the kids would have this opportunity to do online learning, adds Amber Pringle.

Although the COVID-19 pandemic has allowed Ace to learn with the rest of his class, the virus has had an adverse effect on his parents. John and Amber, both small business owners who put their careers on hold to care for Ace, were just getting back to work before the virus reached the city.

Over the past few months, the Pringle family has received assistance from family and friends. Weve really had a lot of support and were extremely thankful to everyone who has helped out, says John Pringle.

Like the rest of the city and the nation, the Pringle family are staying home and keeping safe. Additionally, they are celebrating the fact that Crue will play a crucial role in helping his brother. For now, the family hopes that Ace will soon be in remission so that they can go ahead with the bone marrow transplant.

To help support Ace and his family, consider donating on their GoFundMe page at gofundme.com/f/ace-pringle-leukemia-fundraiser.

More here:
Update: Pacific Beach Elementary student's ongoing battle with leukemia - A few months ago we introduced you to Ace Pringle the first-grader from...

130+ congressmen urge Trump to keep ban on aborted fetal tissue research in race for COVID-19 cure – Lifesite

By Stell Cell Research

WASHINGTON, DC, April 15, 2020 (LifeSiteNews) More than 130 members of Congress urged President Donald Trump to maintain your current fetal tissue research policy and to redirect funds toward ethical, successful alternatives to combat COVID-19.

The pro-life representatives, including House Minority Leader Kevin McCarthy, thanked Trump in an April 14 letter for his decisive actions to protect human life and human dignity on every front, praising him for having brought great hope to our nation.

In the wake of the coronavirus outbreak in the United States, it has been argued by some that Trumps ban on aborted fetal tissue research by government scientists is thwarting efforts to find a remedy for the disease.

A senior scientist at a government biomedical research laboratory has been thwarted in his efforts to conduct experiments on possible treatments for the new coronavirus because of the Trump administrations restrictions on research with human fetal tissue, the Washington Post claimed in March.

Several of the leading COVID-19 vaccine developments, however, are using aborted fetal cells.

15 state Attorneys General had written to President Trump on March 26, stating that the use of aborted fetal tissue could help accelerate vaccine development to combat COVID-19, as well as study the impact to pregnant women and children.

We ask you to end your Fetal Tissue Ban to allow our top scientists the ability to solve this global health crisis, the Attorneys General concluded.

The more than 130 pro-life members of Congress responded to the allegations brought forward by proponents of aborted fetal tissue research, pointing out that they repeat false claims and narratives which for many years have touted the utility of aborted fetal tissue in research, including the claim that aborted fetal tissue has been used to create many vaccines.

The signers of the April 14 letter stressed that fetal tissue from ongoing abortions has never been used in production of a single vaccine. Instead, a few old cell lines from abortions performed in the 1960s and 1970s are used for a small handful of vaccines.

More importantly, most vaccines today use more efficient, modern cell lines and production techniques, the members of Congress explained.

Also, the few attempted transplants of aborted fetal tissue have resulted in making most patients worse, not better, they added.

The members of Congress showed that scientific progress and ethical behavior can go hand in hand.

The focus of the current appeals for taxpayer money to buy fetal tissue is the supposed necessity of using aborted baby body parts to construct humanized mice to test drugs. Yet, this antiquated technology has been surpassed by a plethora of modern, ethical techniques, as has been thoroughly described and cited in Congressional testimony.

Accusing the proponents of aborted fetal tissue research of exploiting the current situation for their own benefit, the pro-life representatives said that holding the line ethically gives us the ability to put resources toward better, more promising science that is already showing potential against COVID-19.

They specifically mentioned three projects.

First, they pointed to humanized mice that already exist, but are not based on aborted fetal tissue.

Then, they talked about [r]epurposing already-approved drugs also showing potential in treating coronavirus patients. At the end of March, the Food and Drug Administration (FDA) authorized experimental coronavirus treatments using anti-malaria drugs chloroquine and hydroxychloroquine.

Finally, they emphasized the great potential of adult stem cells, derived without destroying embryos and without abortion. One specific type of human adult stem cell, they said, has been shown to generate new lung tissue and heal damaged lungs, essential for repair of lungs damaged by respiratory viruses. Another was successful in improving the health of people suffering from pneumonia induced by the coronavirus.

Instrumental in drafting the letter was Congressman Lawrence Lamborn, representing Colorados 5th congressional district since 2007.

During this crisis, the last thing anyone should do is try and advance the lefts radical abortion agenda, Lamborn said. Life is precious at all stages and any claim to the contrary is unconscionable.

He is convinced that a cure for COVID-19 will be found, but using tissue from aborted babies to do so is unethical and wrong. Im thankful that President Trump has taken such a strong stand for life, and Im confident a solution can be found while also maintaining the sanctity of life.

Marjorie Dannenfelser, president of pro-life Susan B. Anthony List, praised the letter in a statement on Wednesday.

As millions of Americans work together to fight the coronavirus outbreak, the profit-driven abortion industry and their allies exploit fears surrounding the pandemic to promote an extreme abortion agenda, she noted.

Abortion supporters insist that unethical experiments involving aborted baby body parts are necessary to find a cure for the coronavirus, ignoring the wide variety of ethical options already available and under development, she continued.

We are greatly encouraged by the strong leadership of Sen. Wicker, Sen. Cindy Hyde-Smith, Rep. Lamborn, Rep. Latta, and all our pro-life allies in Congress who are fighting back against the abortion industrys attempts to exploit this national pandemic to advance their dangerous agenda.

See the original post here:
130+ congressmen urge Trump to keep ban on aborted fetal tissue research in race for COVID-19 cure - Lifesite

The Global Peripheral Nerve Repair Devices Market is expected to grow from USD 5,396.43 Million in 2019 to USD 11,283.48 Million by the end of 2025 at…

By Stell Cell Research

New York, April 15, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Peripheral Nerve Repair Devices Market Research Report by Device, by Application, by End User - Global Forecast to 2025" - https://www.reportlinker.com/p05881975/?utm_source=GNW

"The Neurostimulation & Neuromodulation Device is projected to witness the highest growth during the forecast period"

On the basis of Device, the Peripheral Nerve Repair Devices Market is studied across Biomaterial and Neurostimulation & Neuromodulation Device. The Biomaterial further studied across Nerve Conduit, Nerve Connector, Nerve Protector, and Nerve Wrap. The Neurostimulation & Neuromodulation Device further studied across External Neurostimulation Device and Internal Neurostimulation Device. The Biomaterial commanded the largest size in the Peripheral Nerve Repair Devices Market in 2019. On the other hand, the Neurostimulation & Neuromodulation Device is expected to grow at the fastest CAGR during the forecast period.

"The Nerve Grafting is projected to witness the highest growth during the forecast period"

On the basis of Application, the Peripheral Nerve Repair Devices Market is studied across Direct Nerve Repair/Neurorrhaphy, Nerve Grafting, Neurostimulation & Neuromodulation Surgery, and Stem Cell Therapy. The Direct Nerve Repair/Neurorrhaphy further studied across Epineural Repair, Group Fascicular Repair, and Perineural Repair. The Nerve Grafting further studied across Allograft, Autograft, and Xenograft. The Stem Cell Therapy commanded the largest size in the Peripheral Nerve Repair Devices Market in 2019. On the other hand, the Nerve Grafting is expected to grow at the fastest CAGR during the forecast period.

"The Ambulatory Surgery Center is projected to witness the highest growth during the forecast period"

On the basis of End User, the Peripheral Nerve Repair Devices Market is studied across Ambulatory Surgery Center and Hospital & Clinic. The Hospital & Clinic commanded the largest size in the Peripheral Nerve Repair Devices Market in 2019. On the other hand, the Ambulatory Surgery Center is expected to grow at the fastest CAGR during the forecast period.

"The Asia-Pacific is projected to witness the highest growth during the forecast period"

On the basis of Geography, the Peripheral Nerve Repair Devices Market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region is studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region is studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region is studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. The Americas commanded the largest size in the Peripheral Nerve Repair Devices Market in 2019. On the other hand, the Asia-Pacific is expected to grow at the fastest CAGR during the forecast period.

Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Peripheral Nerve Repair Devices Market including Axogen Inc., Baxter International, Boston Scientific Incorporation, Cyberonics Inc., GlaxoSmithKline Pharmaceuticals Ltd., Integra LifeSciences Corporation, Medovent GmbH, Medtronic PLC, NeuroMetrix, Inc., Orthomed S.A.S., Polyganics B.V., Renerva, LLC,, St. Jude Medical, Stryker Corporation,, Synovis Micro Companies Alliance, Inc., and Toyobo Co., Ltd..

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Peripheral Nerve Repair Devices Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:1. What is the market size and forecast of the Global Peripheral Nerve Repair Devices Market?2. What are the inhibiting factors and their impact analysis shaping the Global Peripheral Nerve Repair Devices Market during the forecast period?3. What is the competitive position if vendors in the Global Peripheral Nerve Repair Devices Market?4. How Porters Five Forces define the Global Peripheral Nerve Repair Devices Market landscape?5. What are the technology trends and regulatory frameworks in the Global Peripheral Nerve Repair Devices Market?6. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Peripheral Nerve Repair Devices Market?7. What is the competitive strategic window for opportunities in the Global Peripheral Nerve Repair Devices Market?8. What arRead the full report: https://www.reportlinker.com/p05881975/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Visit link:
The Global Peripheral Nerve Repair Devices Market is expected to grow from USD 5,396.43 Million in 2019 to USD 11,283.48 Million by the end of 2025 at...

Stem Cell Assay Market : Information, Figures and Analytical Insights 2019-2025 – Germany English News

By Stell Cell Research

Stem Cell Assay Market 2018: Global Industry Insights by Global Players, Regional Segmentation, Growth, Applications, Major Drivers, Value and Foreseen till 2024

The report provides both quantitative and qualitative information of global Stem Cell Assay market for period of 2018 to 2025. As per the analysis provided in the report, the global market of Stem Cell Assay is estimated to growth at a CAGR of _% during the forecast period 2018 to 2025 and is expected to rise to USD _ million/billion by the end of year 2025. In the year 2016, the global Stem Cell Assay market was valued at USD _ million/billion.

This research report based on Stem Cell Assay market and available with Market Study Report includes latest and upcoming industry trends in addition to the global spectrum of the Stem Cell Assay market that includes numerous regions. Likewise, the report also expands on intricate details pertaining to contributions by key players, demand and supply analysis as well as market share growth of the Stem Cell Assay industry.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/13462

Stem Cell Assay Market Overview:

The Research projects that the Stem Cell Assay market size will grow from in 2018 to by 2024, at an estimated CAGR of XX%. The base year considered for the study is 2018, and the market size is projected from 2018 to 2024.

Leading manufacturers of Stem Cell Assay Market:

The major players in the global stem cell assay market include GE Healthcare, Promega Corporation, Thermo Fisher Scientific Inc., Merck KGaA, Cell Biolabs, Inc., Hemogenix Inc., Stemcell Technologies Inc., Bio-Rad Laboratories Inc., R&D Systems Inc., and Cellular Dynamics International Inc.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/13462

Some important highlights from the report include:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/13462

The Questions Answered by Stem Cell Assay Market Report:

And Many More.

Go here to read the rest:
Stem Cell Assay Market : Information, Figures and Analytical Insights 2019-2025 - Germany English News

Mesenchymal Stem Cells Market 2020-2026: Analysed by Business Growth, Development Factors, Applications, and Future Prospects – Science In Me

By Stell Cell Research

The Mesenchymal Stem Cells Market is expected to have a highly positive outlook for the next eight years 2019-2026. This Research Reports emphasizes on key industry analysis, market size, Share, growth and extensive industry dynamics with respect to drivers, opportunities, pricing details and latest trends in the industry.

The global Mesenchymal Stem Cells Market analysis further provides pioneering landscape of market along with market augmentation history and key development involved in the industry. The report also features comprehensive research study for high growth potential industries professional survey with market analysis. Mesenchymal Stem Cells Market report helps the companies to understand the market trends and future market prospective,opportunities and articulate the critical business strategies.

Apply Here For The Sample Copy Of The Report @ https://www.coherentmarketinsights.com/insight/request-sample/720

Geographical segmentation of Mesenchymal Stem Cells Market involves the regional outlook which further covers United States, China, Europe, Japan, Southeast Asia and Middle East & Africa. This report categorizes the market based on manufacturers, regions, type and application.

Mesenchymal Stem Cells Market: Competitive Landscape

Leading players operating in the global Mesenchymal Stem Cells Market include: Pluristem Therapeutics, LonzaThermo, Fisher, ATCC, Bio-Techne, MilliporeSigma, Genlantis, Celprogen, Cell Applications, PromoCell GmbH, Cyagen Biosciences, Human Longevity Inc., Axol Bioscience, Cytori Therapeutics, Eutilex Co.Ltd., ID Pharma Co. Ltd., BrainStrom Cell Therapeutics, Cytori Therapeutics Inc., Neovii Biotech, Angel Biotechnology, California Stem Cell Inc., Stemcelltechnologies Inc., and Celgene Corporation Inc.

Scope of the Report

The key features of the Mesenchymal Stem Cells Market report 2019-2026 are the organization, extensive amount of analysis and data from previous and current years as well as forecast data for the next five years. Most of the report is made up from tables, charts and figures that give our clients a clear picture of the Mesenchymal Stem Cells Market. The structure of Mesenchymal Stem Cells Market by identifying its various segments and sub-segments to help understanding the report.

Mesenchymal Stem Cells Market Research Report gives current competitive analysis and also valuable insights to clients/industries, which will assist them to prepare a new strategy to expand or penetrate in a global Mesenchymal Stem Cells Market.

As the report proceeds further, it covers the analysis of key market participants paired with development plans and policies, production techniques, price structure of the Mesenchymal Stem Cells Market. The report also identifies the other essential elements such as product overview, supply chain relationship, raw material supply and demand statistics, expected developments, profit and consumption ratio.

Get PDF Brochure for Research Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/720

Important Mesenchymal Stem Cells Market Data Available In This Report:

Buy This Research Study Report @ https://www.coherentmarketinsights.com/insight/buy-now/720

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

For More Related Reports: http://bit.ly/Rajkumar123

See the article here:
Mesenchymal Stem Cells Market 2020-2026: Analysed by Business Growth, Development Factors, Applications, and Future Prospects - Science In Me

Stem Cell Therapy Market to 2027 – Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography – Salamanca Press

By Stem Cell Medicine

NEW YORK, April 15, 2020 /PRNewswire/ -- The stem cell therapy market was valued at US$ 1,534.55 million in 2019 and is estimated to reach US$ 5,129.66 million by 2027; it is expected to grow at a CAGR of 16.7% from 2020 to 2027.

Read the full report: https://www.reportlinker.com/p05882135/?utm_source=PRN

The increasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines are the key factor driving the stem cell therapy market. However, high cost related of the stem cell therapy limits the growth of the market.Stem cell research has been widely investigated globally for various medical applications, especially for the treatment of humans.This raises the importance of creating public awareness about stem cell research and its clinical potential.

The main role of stem cells is in the replacement of dying cells and reconstruction of damaged tissues. Based on the extensive stem cell research, many scientists have claimed that these cells could probably be used in the treatment of various diseases, including cancer and cardiovascular disease.There is a large number of potential treatment procedures that are undergoing clinical trials, and a notably few stem cell therapies have won FDA (i.e., US Food and Drug Administration) approval for clinical usage. For instance, in 2019, the FDA approved Fedratinib for the first-line treatment for myelofibrosis. Moreover, stem cell therapies are widely used in bone marrow transplantation, and these therapies have benefited thousands of people suffering from leukemia. Hematopoietic stem cells are used for treating more than 80 medical diseases, including immune system disorders, blood disorders, neurological disorders, metabolic disorders, genetic disorders, and several types of cancers, such as leukemia and lymphoma; this is also likely to boost the demand for this treatment procedure during the forecast period. Researchers are further investigating the use of stem cell therapies in the treatment of autoimmune disorders.

The global stem cell therapy market has been segmented on the basis of type, treatment, application type, and end user.Based on type, the market has been segmented into adult stem cell therapy, induced pluripotent stem cell therapy, embryonic stem cell therapy, and others.

The adult stem cell therapy held the largest share of the market in 2019; however, induced pluripotent stem cell therapy is estimated to register the highest CAGR in the market during the forecast period.Based on treatment, the stem cell therapy market has been segmented into allogeneic and autologous.

The allogeneic segment held a larger share of the market in 2019; however, the market for the autologous segment is expected to grow at a higher CAGR during the forecast period.Based on application type, the stem cell therapy market has been segmented into musculoskeletal, dermatology, cardiology, drug discovery and development, and other applications.

The musculoskeletal segment held the largest share of the stem cell therapy market in 2019, whereas the drug discovery and development segment is expected to report the highest CAGR during 20202027. Based on end user, the market has been segmented into academic and research institutes, and hospitals and specialty clinics. The academic & research institutes held the largest share of the market in 2019, and it is also expected to report the highest CAGR during the forecast period.Several essential secondary sources referred to for preparing this report are the FDA, World Health Organization (WHO), Organisation for Economic Co-operation and Development, National Institutes of Health, Spanish Agency for Medicines (AEMPS), Japanese Society for Regenerative Medicine, and Indian Council of Medical Research, among others.

Read the full report: https://www.reportlinker.com/p05882135/?utm_source=PRN

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________Contact Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Continued here:
Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography - Salamanca Press

UCSD scientists find possibilities for injured brain cells to be repaired – fox5sandiego.com

By Stem Cell Medicine

SAN DIEGO (CNS) Injured adult brain cells revert to an embryonic state and become capable of re-growing new connections, which under the right conditions can help restore lost brain function, according to findings published Wednesday by researchers at UC San Diego School of Medicine.

The findings, published in the academic journal Nature, were part of a collaborative study between UC San Diego, UCLA and the University of Tennessee.

Repairing damage to the brain and spinal cord, until relatively recently, seemed an impossible task. The new study lays out a transcriptional roadmap of regeneration in the adult brain.

Using the incredible tools of modern neuroscience, molecular genetics, virology and computational power, we were able for the first time to identify how the entire set of genes in an adult brain cell resets itself in order to regenerate, said senior author Dr. Mark Tuszynski, professor of neuroscience and director of the Translational Neuroscience Institute at UC San Diego School of Medicine. This gives us fundamental insight into how, at a transcriptional level, regeneration happens.

Using a mouse model, Tuszynski and colleagues discovered that after injury, mature neurons in adult brains revert back to an embryonic state.

Who would have thought, Tuszynski said. Only 20 years ago, we were thinking of the adult brain as static, terminally differentiated, fully established and immutable.

To provide an encouraging environment for regrowth, Tuszynski and colleagues investigated how damaged neurons respond after a spinal cord injury. In recent years, researchers have significantly advanced the possibility of using stem cells to spur spinal cord injury repairs and restore lost function, essentially by inducing neurons to extend nerve fibers through and across an injury site, reconnecting severed nerves.

The latest study produced a second surprise: In promoting neuronal growth and repair, one of the essential genetic pathways involves the gene Huntingtin, which, when mutated, causes Huntington*s disease, a devastating disorder characterized by the progressive breakdown of nerve cells in the brain.

While a lot of work has been done on trying to understand why Huntingtin mutations cause disease, far less is understood about the normal role of Huntingtin, Tuszynski said. Our work shows that Huntingtin is essential for promoting repair of brain neurons. Thus, mutations in this gene would be predicted to result in a loss of the adult neuron to repair itself. This, in turn, might result in the slow neuronal degeneration that results in Huntingtons disease.

Read more here:
UCSD scientists find possibilities for injured brain cells to be repaired - fox5sandiego.com

Cell Therapies Can Revolutionize Treatment, Automation Needed to Scale Production – ENGINEERING.com

By Induced Pluripotent Stem Cells

Parker Hannifin has sponsored this post.

Cell therapies promise treatments for serious illnesses, but require automation and manufacturing expertise to scale up production for research and products. (Image courtesy of Parker Hannifin.)

Cellular therapies and bio-fabrication are two of the most revolutionary treatments for serious illnesses to be developed in the early 21st century, offering the hope of cures where once only symptomatic treatments were available. The 2006 discovery of Induced Pluripotent Stem Cells (iPSCs) formed a catalyst for research and development into these new therapeutic approaches. Stem cell therapies offer promising avenues for the treatment of devastating illnesses such as diabetes, cancer, heart disease and even neurological diseases.

Tailored cell therapies using iPSCs are considered to be the new Third Pillar of the drug and treatment industry, standing alongside small molecules and biologics as tools for treatment. However, the widespread research and treatment using cell therapies requires mass-produced iPSCs to be available in quantitywhich means advanced manufacturing techniques.

Cells are tiny living, complex organisms; they must be handled with precision and accuracy. Automated handling equipment needs a heightened level of dexterity and control. (Image courtesy of Parker Hannifin.)

Scaling up the production of iPSCs requires investmentsome of which is already in place with two deals: $70 million to the New Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) to advance U.S. leadership in the biopharmaceutical industry, and an 87-member coalition funded by the Defense Department called ARMI-BioFab USA, which aims to develop the next-generation techniques needed to repair and replace cells, tissues and organs for wounded military service veterans.

The key to success in the scale-up of production is advanced automation, which will improve the manufacturing process used to fabricate cell colonies.

Currently, most research and cell fabrication involves a significant amount of manual work and decision-making, which can be error-prone and represents a bottleneck in attempts to scale these fabrication processes.

One way to improve the manufacturing processes related to cell therapies is by partnering with experienced automation and manufacturing industry leaders, who can share their expertise. An example of this is the partnership between Parker Hannifin and CellX Technologies. Together, these companies have developed a platform to help researchers and clinicians quantify key morphological stem cells, automate the handling process and perform cell maintenance.

Current cell therapy research is hampered by difficulties with a lack of large field-of-view and high-resolution optics when imaging live cell cultures. This makes it difficult to monitor and quantify changes to the cells. Available devices and equipment for sampling, transfer or deletion of specific cells or colonies also lack the rigorous accuracy that manufacturing-scale production would require. Instead, visual assessment and manual transfer by lab technicians is the usual methodsacrificing speed and production volume.

An automated, image-based system would enable accurate quantitative metrics of biological performance and will be applicable at a cell-by-cell or a colony-by-colony basis, among other benefits.

Automated cell-handling equipment needs to be precise and finely calibrated in order to handle delicate cells with the necessary dexterity and control. Three primary handling techniques are used for this very difficult automation task:

Combining capabilities for these three functions into a single platform will enable multiple benefits, including improved reproducibility and quality of cells for research and products, reduce variability and costs from manual processes, improved lot traceability and documentation, and define quantitative process quality attributes and metrics.

Parker Hannifins expertise in manufacturability, digital pathology and additive manufacturing lends itself directly to the development of the CellX platform. CellX enables automation of the scanning and identification processes, and pairs this with cell selection and precision placement.

The CellX Device, developed by Parker Hannifin and CellX Technologies, combines large field-of-view imaging with precision instrumentation, fluidics, and documentation and control capabilities. (Image courtesy of Parker Hannifin.)

CellX also needed customization of standard products. Parker Hannifin has decades of experience in close tolerance special purpose fluidics and actuator technology, and developed enabling technology for the CellX central core, which consists of a high-quality automated inverted microscope and CCD camera with brightfield and fluorescent imaging capabilities.

Some of the specialized equipment that Parker Hannifin helped develop for CellX includes a load and removal station for disposable cell-picking tips, and environmentally controlled workspace to maintain sterility and oxygen levels, and an integrated sensor to accurately locate each new tip.

The combined precision and imaging capabilities of the CellX platform enable rapid data collection and high repeatability, which means researchers can rely on accurate data, healthy cell colonies and quantitative, reproducible standards for cell therapy development. Parker Hannifin has a proven history of developing new tools and instruments for manufacturing processes with their partner OEMsand in the case of CellX, accelerating the development of the future of cell therapies.

To learn more about Parker Hannifins development of the CellX platform, including use cases and details on the full complement of customized equipment and enabling features, download the full whitepaper from Parker Hannifin.

See more here:
Cell Therapies Can Revolutionize Treatment, Automation Needed to Scale Production - ENGINEERING.com

Stem cell treatment works for many, but insurance doesn’t cover it – msnNOW

By Stem Cell Treatment

Click to expand

UP NEXT

Still waiting for stem cell treatments to come to a doctor's officenear you?

It seems like a decade or two since we were introduced to stem cell research and treatments,and told that, through them,we might beat the degradation of a dreaded disease, recover from an injury or a degenerated joint, and that all these could be things of the past.

All we'd need to do was get an injection of our own stem cells and like magic we'd be up and running again almost like new.Let the body heal itself.Sounds like a dream.

Well in some circles this is more than a dream: Its happening.

Recently I spoke with Mark Berman, a doctor in Beverly Hills, about his Cell Surgical Network: Amore than decade-old business that's busy advancing medical research by using a network of doctor's following specific stem cell protocols.He networks with over 100 doctors in the U.S. and abroad who are enthusiastic about the potential of stem cells and want to see stem cell treatments become a normal part of health care.

To have a betteridea of the protocol, I visited the office of long-time Redding physician Robert Ghelfi, who is in Berman's network.Ghelfiis the medical director of the Northern California Stem Cell Treatment Center that affiliates with several Redding physicians.

He explained the stem cell extraction method: Takea little fat from the patient and spinit to separate the stem cells. Onceseparated, Ghelfiprepares the patients own stem cells forinjection into the injured, damaged or degenerating site on the patient's body.It seems like a surprisingly simple and straightforward procedure. It typically takes one injection,Ghelfisaid, and the visit lasts about an hour.

UP NEXT

Stem cells are attracted to injured, damaged or ill-performing tissue, Berman and Ghelfi explained.Once injected into the region, they begin to heal and regenerate tissue.

How effective is it?

It depends on the area of the body and the problem.

Both Berman and Ghelfi mentioned the 83% success rate they've had with injecting over 6,000 degenerated knees. This treatment is popular with people who opted not to have a knee replacement surgery.

A complication with younger people getting knee replacements is the need for another replacement years later, since the first can wear out. With stem cell therapy, this problem can be avoided, Ghelfi said.

Research shows success with other conditions as well.

For his part, Ghelfi is impressed by the research,and his own clinical experience,using stem cells for the treatment of chronic obstructive pulmonary disease (COPD).

Under the heading of COPDfalls chronic bronchitis and emphysema. Since chronic bronchitis usually progresses to emphysema, Ghelfis goalis to try to stabilize pulmonary function.

"This is a huge improvement for COPD since the rate of decline annually is fourpercent," he said. And since pulmonary function is easily measurable, it works nicely forresearch data.

More stories:

Shasta County declares coronavirus emergency; Redding expected to do the same

Coronavirus: As schools close, some districts in rural California make tough call to stay open

Coronavirus updates: Kool April Nites canceled; Win-River Resort & Casino closed

Success has been reported by injecting stem cells into disc protrusions, thumbs, fingers, wrists, elbows, ankles, hips, necks, backs, tendons and for treating non-healing wounds, congestive heart failure, Parkinson's disease, peripheral neuropathy, asthma, multiple sclerosis, lupus and rheumatoid arthritis.

As research continues to be compiled by participating doctors, the body of work into stem cell applications increases.

Berman and Ghelfi are both surgeons who've become interested in stem cell therapies because of the results theyve achieved, their ease of use and lack of side effects.

Stem cell research is still in its relative infancy, and I have no doubt that these pioneers will be moving the needle in healthcare not only in the United States, but worldwide.

Note: This stem cell procedure is not covered by insurance and the cost is between $5,000 and $7,000for treatment, Ghelfi said. If you think you have a health situation that might benefit from stem cell treatment, he offers a free consultation.

Research and treatments have shown promise.More options are always good.

Trudi Pratt has a chiropractic and clinical nutrition practice in Redding.Reach her athttp://www.drtrudipratt.com/ or at 244-7873.

This article originally appeared on Redding Record Searchlight: Stem cell treatment works for many, but insurance doesn't cover it

Go here to see the original:
Stem cell treatment works for many, but insurance doesn't cover it - msnNOW

→←